STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure.
Cannone, Valentina; Ledwidge, Mark; Watson, Chris; McKie, Paul M; Burnett, John C; McDonald, Kenneth
B-type natriuretic peptide (BNP) possesses blood-pressure-lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.
Keywords: B-type natriuretic peptide; BNP, B-type natriuretic peptide; HF, heart failure; LVSD, left ventricular systolic dysfunction; RAAS, renin-angiotensin-aldosterone system; SNP, single nucleotide polymorphism; STOP-HF Trial; heart failure; pGC-A, particulate guanylyl cyclase A receptor; rs198389; single nucleotide polymorphism.
↧